Clinical cancer research has yielded tremendous gains, leading to longersurvivalandbetterqualityoflifeforthem…
Americans diagnosed with the disease each year. Great strides in cancer prevention have …

Background The increased use of the androgen receptor axis-targeted (ARAT) agents
abiraterone and enzalutamide in first-and second-line treatment of metastatic castration …

Molecularly targeted therapies for advanced prostate cancer include castration modalities
that suppress ligand-dependent transcriptional activity of the androgen receptor (AR) …

Background The activity of enzalutamide after prior treatment with both abiraterone acetate
(abiraterone) and docetaxel has been examined in several retrospective studies. However …

Desmoplastic small round cell tumor (DSRCT) is an aggressive, usually incurable sarcoma
subtype that predominantly occurs in post-pubertal young males. Recent evidence suggests …

Background AZD3514 is a first-in-class, orally bio-available, androgen-dependent and-
independent androgen receptor inhibitor and selective androgen-receptor down-regulator …

Prostate cancer transitions from an early treatable form to the lethal castration-resistant
prostate cancer (CRPC). Androgen receptor (AR) and constitutively active AR splice …

Prostate cancer is the second leading cause of cancer-related deaths in men in most
western countries. New agents for metastatic castration-resistant prostate cancer (CRPC) …

Persistent androgen signaling is functionally significant in castration-resistant prostate
cancer (CRPC) and it is actually considered a validated therapeutic target. Residual intra …

The treatment landscape of castration-resistant prostate cancer (CRPC) has been
dramatically changed over the past years with the approval of several new drugs for clinical …